Local and Systemic Antimicrobials in Periodontitis Stages 2 and 3

The main treatment of every patient with periodontitis is non-surgical periodontal treatment (NSPT) with the ultimate goal to arrest inflammation. Given the biofilm microorganisms associated etiology of the periodontitis, NSPT can be combined with adjunctive antimicrobial therapy. Hence, this randomized clinical trial aims to compare the clinical and microbiological effectiveness and relative expression levels (REL) of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) between local and systemic antibiotics as adjunctive therapy to NSPT in patents with periodontitis stages 2 and 3.

Inclusion Criteria:Both sexes, older than 18 yearsPatients diagnosed with stage 2 or 3 periodontitis, who are willing to participate in the research and who have signed an informed consentThe presence of at least three teeth per quadrant (except third molars), as well as the presence of at least two teeth with a probing depth of more than 5mm in each quadrantPatients who did not receive antibiotic therapy of any kind for a minimum of three months prior to inclusion in the studySystemically healthy patientsNon-smokers or smokers up to 10 cigarettes/day (light smokers)Exclusion Criteria:Patients allergic to penicillin or penicillin derivativesPresence of systemic diseasesThe presence of local infections that can compromise the results of therapyPregnancy and lactation